Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay

Autores
Saade, Ursula; de Boer, Jasper; Scandale, Ivan; Altcheh, Jaime Marcelo; Pottel, Hans; Chatelain, Eric; Zrein, Maan
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a serological multiplex method (MultiCruzi), combined with advanced statistical analytical methods, to measure the response to anti-parasitic treatment of adult Chagas patients. Applying this approach to serum samples from adult patients in the indeterminate chronic stage of Chagas disease, treated with different benznidazole regimens and combinations, we predict treatment efficacy after just 6 months of follow-up, in sharp contrast to data obtained with conventional and recombinant T. cruzi ELISA tests. The obtained results are also compared with the PCR data. We propose integrating MultiCruzi as a serological method endpoint in proof-of-concept clinical trials for Chagas disease.
Fil: Saade, Ursula. Infynity Biomarkers; Francia. Swiss Tropical and Public Health Institute; Suiza. University of Basel; Suiza
Fil: de Boer, Jasper. Katholikie Universiteit Leuven; Bélgica
Fil: Scandale, Ivan. Drugs for Neglected Diseases initiative; Suiza
Fil: Altcheh, Jaime Marcelo. Gobierno de la Ciudad de Buenos Aires. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez". Servicio de Parasitología y Chagas; Argentina
Fil: Pottel, Hans. Katholikie Universiteit Leuven; Bélgica
Fil: Chatelain, Eric. Drugs for Neglected Diseases initiative; Suiza
Fil: Zrein, Maan. Infynity Biomarkers; Francia
Materia
Chagas
Biomarkers
Treatment
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/267627
Acceder
id CONICETDig_ab0ef122ba696d85653c133738fb2ac8
oai_identifier_str oai:ri.conicet.gov.ar:11336/267627
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassaySaade, Ursulade Boer, JasperScandale, IvanAltcheh, Jaime MarceloPottel, HansChatelain, EricZrein, MaanChagasBiomarkersTreatmenthttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a serological multiplex method (MultiCruzi), combined with advanced statistical analytical methods, to measure the response to anti-parasitic treatment of adult Chagas patients. Applying this approach to serum samples from adult patients in the indeterminate chronic stage of Chagas disease, treated with different benznidazole regimens and combinations, we predict treatment efficacy after just 6 months of follow-up, in sharp contrast to data obtained with conventional and recombinant T. cruzi ELISA tests. The obtained results are also compared with the PCR data. We propose integrating MultiCruzi as a serological method endpoint in proof-of-concept clinical trials for Chagas disease.Fil: Saade, Ursula. Infynity Biomarkers; Francia. Swiss Tropical and Public Health Institute; Suiza. University of Basel; SuizaFil: de Boer, Jasper. Katholikie Universiteit Leuven; BélgicaFil: Scandale, Ivan. Drugs for Neglected Diseases initiative; SuizaFil: Altcheh, Jaime Marcelo. Gobierno de la Ciudad de Buenos Aires. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez". Servicio de Parasitología y Chagas; ArgentinaFil: Pottel, Hans. Katholikie Universiteit Leuven; BélgicaFil: Chatelain, Eric. Drugs for Neglected Diseases initiative; SuizaFil: Zrein, Maan. Infynity Biomarkers; FranciaNature2024-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/267627Saade, Ursula; de Boer, Jasper; Scandale, Ivan; Altcheh, Jaime Marcelo; Pottel, Hans; et al.; Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay; Nature; Nature Communications; 15; 1; 12-2024; 1-122041-1723CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/s41467-024-54910-xinfo:eu-repo/semantics/altIdentifier/doi/10.1038/s41467-024-54910-xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:14:00Zoai:ri.conicet.gov.ar:11336/267627instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:14:00.629CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
title Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
spellingShingle Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
Saade, Ursula
Chagas
Biomarkers
Treatment
title_short Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
title_full Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
title_fullStr Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
title_full_unstemmed Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
title_sort Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay
dc.creator.none.fl_str_mv Saade, Ursula
de Boer, Jasper
Scandale, Ivan
Altcheh, Jaime Marcelo
Pottel, Hans
Chatelain, Eric
Zrein, Maan
author Saade, Ursula
author_facet Saade, Ursula
de Boer, Jasper
Scandale, Ivan
Altcheh, Jaime Marcelo
Pottel, Hans
Chatelain, Eric
Zrein, Maan
author_role author
author2 de Boer, Jasper
Scandale, Ivan
Altcheh, Jaime Marcelo
Pottel, Hans
Chatelain, Eric
Zrein, Maan
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Chagas
Biomarkers
Treatment
topic Chagas
Biomarkers
Treatment
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a serological multiplex method (MultiCruzi), combined with advanced statistical analytical methods, to measure the response to anti-parasitic treatment of adult Chagas patients. Applying this approach to serum samples from adult patients in the indeterminate chronic stage of Chagas disease, treated with different benznidazole regimens and combinations, we predict treatment efficacy after just 6 months of follow-up, in sharp contrast to data obtained with conventional and recombinant T. cruzi ELISA tests. The obtained results are also compared with the PCR data. We propose integrating MultiCruzi as a serological method endpoint in proof-of-concept clinical trials for Chagas disease.
Fil: Saade, Ursula. Infynity Biomarkers; Francia. Swiss Tropical and Public Health Institute; Suiza. University of Basel; Suiza
Fil: de Boer, Jasper. Katholikie Universiteit Leuven; Bélgica
Fil: Scandale, Ivan. Drugs for Neglected Diseases initiative; Suiza
Fil: Altcheh, Jaime Marcelo. Gobierno de la Ciudad de Buenos Aires. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas; Argentina. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños "Ricardo Gutiérrez". Servicio de Parasitología y Chagas; Argentina
Fil: Pottel, Hans. Katholikie Universiteit Leuven; Bélgica
Fil: Chatelain, Eric. Drugs for Neglected Diseases initiative; Suiza
Fil: Zrein, Maan. Infynity Biomarkers; Francia
description Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a serological multiplex method (MultiCruzi), combined with advanced statistical analytical methods, to measure the response to anti-parasitic treatment of adult Chagas patients. Applying this approach to serum samples from adult patients in the indeterminate chronic stage of Chagas disease, treated with different benznidazole regimens and combinations, we predict treatment efficacy after just 6 months of follow-up, in sharp contrast to data obtained with conventional and recombinant T. cruzi ELISA tests. The obtained results are also compared with the PCR data. We propose integrating MultiCruzi as a serological method endpoint in proof-of-concept clinical trials for Chagas disease.
publishDate 2024
dc.date.none.fl_str_mv 2024-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/267627
Saade, Ursula; de Boer, Jasper; Scandale, Ivan; Altcheh, Jaime Marcelo; Pottel, Hans; et al.; Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay; Nature; Nature Communications; 15; 1; 12-2024; 1-12
2041-1723
CONICET Digital
CONICET
url http://hdl.handle.net/11336/267627
identifier_str_mv Saade, Ursula; de Boer, Jasper; Scandale, Ivan; Altcheh, Jaime Marcelo; Pottel, Hans; et al.; Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay; Nature; Nature Communications; 15; 1; 12-2024; 1-12
2041-1723
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.nature.com/articles/s41467-024-54910-x
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41467-024-54910-x
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature
publisher.none.fl_str_mv Nature
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614062741127168
score 13.070432

Publicaciones similares